Search results for " Aggregation"

showing 10 items of 441 documents

Protein Aggregation in Muscle Fibers and Respective Neuromuscular Disorders

2007

Protein aggregation in muscle fibers may be a nonspecific phenomenon such as occurring in cores or ragged red fibers. However, it may also be a disease-specific and disease-significant phenomenon constituting protein aggregate myopathies (PAMs). These may be divided into two classes: The first one is marked by impaired extralysosomal degradation of proteins, catabolic PAM, encompassing desmin-related myopathies. Mutant proteins, that is, desmin, myotilin, or α-B crystallin, defy protein degradation, aggregate and associate with other proteins within muscle fibers, hence marking desminopathies, myotilinopathies, and α-B crystallinopathies. A second class of PAM encompasses those apparently a…

Nemaline myopathyCrystallinChemistryMyosinmedicineMyotilinDesminProtein degradationProtein aggregationmedicine.diseaseMyofibrilCell biology
researchProduct

Glial and neuronal expression of polyglutamine proteins induce behavioral changes and aggregate formation inDrosophila

2004

Patients with polyglutamine expansion diseases, like Huntington's disease or several spinocerebellar ataxias, first present with neurological symptoms that can occur in the absence of neurodegeneration. Behavioral symptoms thus appear to be caused by neuronal dysfunction, rather than cell death. Pathogenesis in polyglutamine expansion diseases is largely viewed as a cell-autonomous process in neurons. It is likely, however, that this process is influenced by changes in glial physiology and, at least in the case of DRPLA glial inclusions and glial cell death, seems to be an important part in the pathogenesis. To investigate these aspects in a Drosophila model system, we expressed polyglutami…

Nervous systemProgrammed cell deathCentral nervous systemNeurodegenerationProtein aggregationBiologymedicine.diseasePathogenesisCellular and Molecular Neurosciencemedicine.anatomical_structurenervous systemNeurologymedicineSpinocerebellar ataxiaNeurogliaNeuroscienceGlia
researchProduct

Nucleation mechanisms and spatial hetereogeneity in insulin amyloid fibrils formation

2008

Nucleation protein aggregation insulin
researchProduct

An algorithm for simulating end-user behaviour in a real time pricing market

2015

The energy market has changed radically over the last decade, mainly due to an increased penetration of renewable energies. Now the end users have directly access to the energy market and can actively take part to the electricity market. Electricity customers can indeed modify their behavior through Demand Response, namely by means of pricing strategies that support a change in the end-users habits. This can be accomplished through a 'loads aggregator', a third party that collects the requests and signals for Active Demand-based services coming from the markets and the different actors of energy market. This paper describes a simulation framework to generate the simulated optimal behavior o…

Operations researchbusiness.industryComputer scienceEnd userReal-time pricingDemand Responsesimulationcomputer.software_genreNews aggregatorSettore ING-IND/33 - Sistemi Elettrici Per L'EnergiaDemand responsecase studyloads aggregationPricing strategiesVariable pricingElectricity marketEnergy marketElectricitybusinesscomputer2015 IEEE 15th International Conference on Environment and Electrical Engineering (EEEIC)
researchProduct

Real-time pricing for aggregates energy resources in the Italian energy market

2015

Abstract Over the last decade, the architecture of the energy market has radically changed. In many countries end-users are now able to directly access the market, which has given rise to the question of how they can actively participate in that market. End-users can comprise a critical mass through aggregation that is carried out by a third party – to wit the “loads aggregator.” This paper proposes a new framework for generating feasible real-time price curves for those end-users in a demand-response management process. The underlying algorithm generates output curves as the solution to a constrained optimization problem whose objective function is the aggregator's economic benefit. A case…

OptimizationReal time pricingThird partyMechanical EngineeringEnergy resourcesReal time pricingBuilding and Constructioncomputer.software_genrePollutionIndustrial and Manufacturing EngineeringNews aggregatorMicroeconomicsCritical mass (sociodynamics)Settore ING-IND/33 - Sistemi Elettrici Per L'EnergiaGeneral EnergyCommerceEconomicsEnergy marketElectrical and Electronic EngineeringArchitecturecomputerManagement processLoads aggregationCivil and Structural Engineering
researchProduct

P53 Aggregates and Interacts with Tau in Alzheimer's Disease

2020

P53Alzheimer's diseaseTauprotein aggregation
researchProduct

Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease

2015

Neurofibrillary tangles (aggregates of cytoskeletal Tau protein) and senile plaques (aggregates mainly formed by amyloid β peptide) are two landmark lesions in Alzheimer׳s disease. Some researchers have proposed tangles, whereas others have proposed plaques, as primary lesions. For a long time, these were thought of as independent mechanisms. However, experimental evidence suggests that both lesions are intimately related. We review here some molecular pathways linking amyloid β and Tau toxicities involving, among others, glycogen synthase kinase 3β, p38, Pin1, cyclin-dependent kinase 5, and regulator of calcineurin 1. Understanding amyloid β and Tau toxicities as part of a common pathophys…

Pathologymedicine.medical_specialtyAmyloid beta-PeptidesbiologyChemistryKinaseNeurodegenerationTau proteinBACE1-AStau Proteinsmedicine.diseaseProtein Aggregation PathologicalBiochemistryBiochemistry of Alzheimer's diseaseAlzheimer DiseaseGSK-3Physiology (medical)mental disordersmedicinebiology.proteinCancer researchPIN1HumansSenile plaquesPhosphorylationFree Radical Biology and Medicine
researchProduct

Microvascular in vivo assessment of reperfusion injury: significance of prostaglandin E1 and I2 in postischemic “no-reflow” and “reflow-paradox”

2004

Microvascular ischemia-reperfusion (I/R) injury is characterized by failure of capillary perfusion ("no-reflow") and reoxygenation-associated phenomena ("reflow-paradox"), including activation of leukocyte-endothelium interaction with cytotoxic mediator-induced loss of endothelial integrity. The objectives of this study were to elucidate the impact of both prostaglandins E(1) (PGE(1)) and I(2) (PGI(2)) in microvascular reperfusion injury, with special focus on the distinct pathophysiology of no-reflow- and reflow-paradox phenomena.By use of the hamster dorsal skinfold preparation and in vivo fluorescence microscopy, the microcirculation of a striated skin muscle was assessed before 4 h of p…

Pathologymedicine.medical_specialtyEndotheliummedicine.medical_treatmentIschemiaPharmacologyMicrocirculationCapillary Permeabilitychemistry.chemical_compoundIn vivoCricetinaemedicineAnimalsVascular Diseasescardiovascular diseasesAlprostadilMuscle SkeletalProstaglandin E1SkinMicroscopyMesocricetusbusiness.industryMicrocirculationmedicine.diseaseEpoprostenolPathophysiologyCapillariesChemotaxis Leukocytemedicine.anatomical_structurechemistryReperfusion InjuryModels Animalcardiovascular systemSurgeryEndothelium VascularbusinessReperfusion injuryPlatelet Aggregation InhibitorsProstaglandin EJournal of Surgical Research
researchProduct

C-reactive protein and efficacy of antiplatelet therapy in (intracranial) atherosclerosis

2018

C-reactive protein (CRP) and other inflammatory biomarkers can indicate both the severity and extent of atherosclerosis, reflecting the inflammatory nature of the disease process.1 Atherogenesis begins with an inflammatory response to vascular injury with cells and mediators initiating the healing response and later inducing growth of atherosclerotic plaques. Inflammation then increases plaque instability, promoting rupture, fissuring, or erosion—the pathogenetic milieu of thrombosis in atherothrombotic ischemic strokes.

Pathologymedicine.medical_specialtyInflammationConstriction PathologicDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineHumansbiologyC-reactive protein intracranial atherosclerosisbusiness.industryIschemic strokesC-reactive proteinAtherosclerosismedicine.diseaseThrombosisInflammatory biomarkersC-Reactive Proteinbiology.proteinPlatelet aggregation inhibitorNeurology (clinical)Intracranial Atherosclerosismedicine.symptombusinessPlatelet Aggregation Inhibitors030217 neurology & neurosurgeryNeurology
researchProduct

156th ENMC International Workshop: desmin and protein aggregate myopathies, 9-11 November 2007, Naarden, The Netherlands.

2008

Pathologymedicine.medical_specialtyProtein aggregationBiologyDesminNeurologyMuscular DiseasesPediatrics Perinatology and Child HealthmedicineMyotilinHumansDesminNeurology (clinical)Muscle SkeletalGenetics (clinical)Neuromuscular disorders : NMD
researchProduct